Roche said on Thursday it had agreed to buy 454 Life Sciences Corp. from CuraGen for up to $154.9 million.
Roche will pay 454 Life Science's shareholders $140 million in cash.
They may also receive a further $14.9 million in cash from holders of currently outstanding stock options and warrants, if these are exercised, Roche said in a statement.
Reuters
No comments:
Post a Comment